Journal Article Review Ppublish
PubMed: 39872253 DOI: 10.25259/ijn_491_23
Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.
Indian J Nephrol 35(1):8-20
Authors: Kenar D Jhaveri, Priti Meena, Joyita Bharati, Srikanth Bathini
Affiliations
- Department of Nephrology, The Glomerular Disease Center at Northwell Health, Co-Director, Onconephrology Services Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
- Department of Nephrology, All India Institute Medical Sciences, Bhubaneswar, India.
- Section of Nephrology, Boston Medical Center and Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
- Department of Nephrology, Asian Institute of Nephrology and Urology, Dilsukhnagar Hyderabad, India.
Abstract
Multiple myeloma (MM) represents a difficult-to-treat plasma cell malignancy and the second most common hematologic malignancy in adults, significantly impacting kidney function. The spectrum of kidney involvement in MM is broad, encompassing electrolyte imbalances, tubular injury, and even rare glomerular diseases. The evolution of MM treatment modalities has led to notable improvements in the long-term survival of patients experiencing kidney-related complications. Over the past decade, groundbreaking therapeutic agents have emerged, including proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, selective inhibitors of nuclear export, and antibody-drug conjugates. These novel therapies have revolutionized the landscape of MM management, offering new hope for patients and challenging the traditional treatment paradigms. This comprehensive review explores recent advances in the diagnosis and management of MM, emphasizing the pivotal role of these innovative therapeutic agents in improving patient outcomes. We delve into the intricacies of diagnosing MM, highlighting the significance of early detection and precise diagnostic tools. We elucidate the evolving treatment strategies, emphasizing the mechanisms of action and clinical efficacy of the latest agents. This manuscript provides valuable insights into the ever-evolving field of MM management, shedding light on the remarkable progress achieved in enhancing the prognosis and quality of life of MM patients.
MeSH
Kidney Diseases, Pharmaceutical Preparations, Neoplasms, Kidney, Multiple Myeloma, Diagnosis, Therapeutics